ERBB2 and neoplasm: These metabolic adaptations correlate with anatomical subtypes (e.g., ERBB2-amplified iCCA vs. PIK3CA-mutant extrahepatic tumours) and influence chemotherapy/targeted therapy efficacy (88–90).